SGFG
PMVP icon

Silver Grove Financial Group’s PMV Pharmaceuticals PMVP Stock Holding History

Silver Grove Financial Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.81K Hold
5,082
– – ﹤0.01% 1061
2026
Q1 		$6.3K Hold
5,082
– – 0.01% 348
2025
Q4 		$6.35K Buy
+5,082
New +$6.81K 0.01% 133

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Silver Grove Financial Group's PMVP Position: Q2 2026 in Review

Silver Grove Financial Group held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 5,082 shares worth $6.81K. The position accounts for ﹤0.01% of the portfolio, ranked #1061.

Silver Grove Financial Group first reported a position in PMVP in Q4 2025 and has held it in 3 quarters since. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Silver Grove Financial Group held 5,082 shares of PMV Pharmaceuticals worth $6.81K as of Q2 2026.
  • Silver Grove Financial Group left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1061 holding.
  • Silver Grove Financial Group first reported a position in PMV Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.